Filing Flows

Filing Flows › Companies › Caribou Biosciences › Cash flow

Caribou Biosciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$22.5M in Q3 2026 · −$93.0M over twelve months

Operating cash flow−$22.5M
Capital spending−$19K
Free cash flow−$22.5M

Analysis

In Q3 2026, Caribou Biosciences generated −$22.5M of operating cash flow and spent $19K on capital projects, leaving free cash flow of −$22.5M. That is $2.8M more than in Q3 2025 (−$25.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$93.1M; the largest uses were operating cash flow ($93.1M); besides operations, cash came from other investing ($79.8M), shares issued ($27.7M); the cash balance rose by $14.9M.

Operating cash flow was −$22.5M against net income of −$26.6M. The largest differences: stock-based pay +$2.2M, payables +$2.0M, prepaid and other assets −$1.1M.

Free cash flow

Caribou Biosciences: free cash flow by quarterCaribou Biosciences: free cash flow by quarter−$36.0MQ4 2024−$37.8MQ1 2025−$28.7MQ2 2025−$25.3MQ3 2025−$20.6MQ4 2025−$27.1MQ1 2026−$22.8MQ2 2026−$22.5MQ3 2026
Operating cash flow less capital spending.
Caribou Biosciences: operating cash flow against capital spendingCaribou Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$35.5M$518KQ4 2024−$36.7M$1.0MQ1 2025−$28.3M$418KQ2 2025−$25.2M$115KQ3 2025−$20.8M−$216KQ4 2025−$27.0M$72KQ1 2026−$22.8M$1KQ2 2026−$22.5M$19KQ3 2026
Latest (Q3 2026): Operating cash flow −$22.5M, Capital spending $19K.

Capital allocation, year by year

Caribou Biosciences: where the cash came from (up) and went (down), by fiscal yearCaribou Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$32.5MFY2021: Net borrowing −$119KFY2021: Shares issued $432MFY2021: Capital spending −$2.1M$432MFY2021FY2022: Operating cash flow −$91.0MFY2022: Capital spending −$6.5MFY2022FY2023: Operating cash flow −$93.3MFY2023: Shares issued $1.0MFY2023: Capital spending −$11.6M$1.0MFY2023FY2024: Operating cash flow −$138MFY2024: Shares issued $16.1MFY2024: Asset sales $13KFY2024: Capital spending −$4.9M$16.1MFY2024FY2025: Operating cash flow −$111MFY2025: Shares issued $4.8MFY2025: Capital spending −$1.4M$4.8MFY2025
Over these 5 years operating cash flow totalled −$466M; the largest uses were operating cash flow ($466M) and capital spending ($26.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$94.8M
Debtnone
Net cash$94.8M
Cash runway12 months

Caribou Biosciences is burning cash: its operations consume cash, a free cash flow of −$93.0M a year at the current rate against $94.8M of cash and investments: a runway of about 12 months before any new financing.

Where the cash came from and went

Caribou Biosciences: sources (+) and uses (−) of cash, Q3 2026Caribou Biosciences: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$22.5MOther investing$19.4MShares issued$3.0MCash drawn (+) / kept (−)$137KCapital spending−$19KOther financing$10K
Caribou Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Caribou Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$93.1MOther investing$79.8MShares issued$27.7MCash drawn (+) / kept (−)−$14.9MAsset & business sales$317KCapital spending$124KOther financing$31K

From profit to cash

Caribou Biosciences: net income to operating cash flow, Q3 2026Caribou Biosciences: net income to operating cash flow, Q3 2026Net income−$26.6MDepreciation & amortization$590KStock-based pay$2.2MGains on disposals−$254KReceivables−$315KPayables$2.0MAccrued liabilities$126KDeferred revenue−$55KContract assets−$20KPrepaid and other assets−$1.1MOperating cash flow−$22.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$22.5M−$19K$3.0M$137K−$22.5M
Q2 2026−$22.8M−$1K$17.9M−$14.1M−$22.8M
Q1 2026−$27.0M−$72K$2.7M$303K−$27.1M
Q4 2025−$20.8M$216K$4.1M−$1.2M−$20.6M
Q3 2025−$25.2M−$115K$277K$14.1M−$25.3M
Q2 2025−$28.3M−$418K—$4.2M−$28.7M
Q1 2025−$36.7M−$1.0M$468K−$13.1M−$37.8M
Q4 2024−$35.5M−$518K$3.9M$15.7M−$36.0M

Caribou Biosciences: income statement and cash flow

Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year). The chart follows the revenue to costs, profit and cash.

Caribou Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.